Viking Therapeutics, Inc. (0VQA.L)
USD 39.07
(-17.95%)
USD 39.07
(-17.95%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -100.82 Million USD | -43.4% |
| 2022 | -70.35 Million USD | -26.26% |
| 2021 | -55.39 Million USD | -30.41% |
| 2020 | -42.66 Million USD | -67.31% |
| 2019 | -25.37 Million USD | -17.91% |
| 2018 | 4.66 Million USD | -12.19% |
| 2017 | 442.88 Thousand USD | -49.32% |
| 2016 | 1.14 Million USD | 42.37% |
| 2015 | -22.38 Million USD | -5.49% |
| 2014 | -21.25 Million USD | -17365.78% |
| 2013 | -121.69 Thousand USD | -2195029.87% |
| 2012 | -109.64 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -33.99 Million USD | -16.39% |
| 2024 Q2 | -33.97 Million USD | -0.16% |
| 2024 Q3 | -36.46 Million USD | -7.35% |
| 2023 Q1 | -20.53 Million USD | -1.25% |
| 2023 Q3 | -27.26 Million USD | -14.85% |
| 2023 Q2 | -23.74 Million USD | -15.6% |
| 2023 Q4 | -29.21 Million USD | -7.14% |
| 2023 FY | - USD | -42.98% |
| 2022 Q4 | -20.28 Million USD | -26.34% |
| 2022 Q2 | -17.58 Million USD | -8.79% |
| 2022 Q1 | -16.16 Million USD | -29.17% |
| 2022 FY | - USD | -26.26% |
| 2022 Q3 | -16.05 Million USD | 8.73% |
| 2021 FY | - USD | -30.41% |
| 2021 Q3 | -13.32 Million USD | 12.81% |
| 2021 Q1 | -14.15 Million USD | -25.39% |
| 2021 Q2 | -15.28 Million USD | -7.99% |
| 2021 Q4 | -12.51 Million USD | 6.08% |
| 2020 FY | - USD | -67.31% |
| 2020 Q4 | -11.29 Million USD | -15.53% |
| 2020 Q3 | -9.77 Million USD | 7.39% |
| 2020 Q2 | -10.55 Million USD | 3.03% |
| 2020 Q1 | -10.88 Million USD | -46.07% |
| 2019 FY | - USD | -17.91% |
| 2019 Q4 | -7.45 Million USD | -29.86% |
| 2019 Q3 | -5.73 Million USD | 25.24% |
| 2019 Q2 | -7.67 Million USD | -55.91% |
| 2019 Q1 | -4.92 Million USD | 5.85% |
| 2018 Q2 | -6.52 Million USD | -98.18% |
| 2018 FY | - USD | -12.19% |
| 2018 Q4 | -5.22 Million USD | 20.79% |
| 2018 Q3 | -6.6 Million USD | -1.13% |
| 2018 Q1 | -3.29 Million USD | 13.94% |
| 2017 Q4 | -3.82 Million USD | 34.52% |
| 2017 Q3 | -5.84 Million USD | -20.88% |
| 2017 Q2 | -4.83 Million USD | -0.93% |
| 2017 Q1 | -4.78 Million USD | -49.18% |
| 2017 FY | - USD | -49.32% |
| 2016 Q3 | -3.37 Million USD | -6.59% |
| 2016 FY | - USD | 42.37% |
| 2016 Q1 | -3.17 Million USD | 34.45% |
| 2016 Q2 | -3.16 Million USD | 0.15% |
| 2016 Q4 | -3.21 Million USD | 4.87% |
| 2015 Q1 | -5.5 Million USD | -420.53% |
| 2015 Q2 | -7.59 Million USD | -37.98% |
| 2015 Q4 | -4.83 Million USD | -7.83% |
| 2015 Q3 | -4.48 Million USD | 40.94% |
| 2015 FY | - USD | -5.49% |
| 2014 Q1 | -219.98 Thousand USD | -1048.45% |
| 2014 Q2 | -22.71 Million USD | -10224.6% |
| 2014 Q3 | -40.09 Thousand USD | 99.82% |
| 2014 Q4 | 1.71 Million USD | 4382.93% |
| 2014 FY | - USD | -17365.78% |
| 2013 Q1 | -3227.00 USD | 97.06% |
| 2013 Q3 | -19.15 Thousand USD | -12.97% |
| 2013 Q4 | -19.15 Thousand USD | 0.0% |
| 2013 Q2 | -16.95 Thousand USD | -425.44% |
| 2013 FY | - USD | -2195029.87% |
| 2012 Q4 | -109.64 Thousand USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | 38.187% |
| Dynavax Technologies Corporation | 9.66 Million USD | 1143.11% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 202.61% |
| Perrigo Company plc | 646.2 Million USD | 115.603% |
| Illumina, Inc. | -608 Million USD | 83.417% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 100.934% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 77.545% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.106% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 103.097% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 2.857% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 102.166% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -170.437% |
| Waters Corporation | 1.02 Billion USD | 109.863% |
| Biogen Inc. | 2.37 Billion USD | 104.242% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -15.327% |
| Evolus, Inc. | -41.81 Million USD | -141.155% |
| Adicet Bio, Inc. | -136.53 Million USD | 26.153% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 14.299% |
| bluebird bio, Inc. | -167.16 Million USD | 39.683% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 32.83% |
| FibroGen, Inc. | -261.4 Million USD | 61.429% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 106.012% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -126.9% |
| Homology Medicines, Inc. | -47.75 Million USD | -111.129% |
| Geron Corporation | -174.78 Million USD | 42.313% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 55.801% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -9.501% |
| Myriad Genetics, Inc. | -67.8 Million USD | -48.712% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 80.086% |
| Zoetis Inc. | 3.68 Billion USD | 102.736% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -99.373% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 108.662% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 132.495% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 102.189% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -179.439% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 56.164% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 62.095% |
| Verastem, Inc. | -83.16 Million USD | -21.236% |
| Nektar Therapeutics | -243.1 Million USD | 58.526% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 55.186% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -14.596% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 77.043% |
| OPKO Health, Inc. | -65.51 Million USD | -53.897% |
| Exelixis, Inc. | 196.6 Million USD | 151.285% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 124.231% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 193.079% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -80.836% |
| uniQure N.V. | -253.1 Million USD | 60.163% |
| Imunon, Inc. | -20.78 Million USD | -385.159% |
| Blueprint Medicines Corporation | -474.61 Million USD | 78.756% |
| Insmed Incorporated | -654.73 Million USD | 84.6% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 122.309% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 70.814% |
| TG Therapeutics, Inc. | 26.1 Million USD | 486.31% |
| Incyte Corporation | 919.42 Million USD | 110.966% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 80.046% |